Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H5N1 vaccines - National Resilience

Next Previous
Drug Profile

Influenza A virus H5N1 vaccines - National Resilience

Alternative Names: A/H5N1 pre-pandemic influenza vaccine (whole virion, vero cell derived, inactivated); Cell culture-based pandemic avian influenza (bird flu) vaccine - Takeda; Cell cultured influenza H5N1 vaccine prototype; Cell cultured influenza pre-pandemic H5N1 vaccine; Celvapan H5N1 vaccine - Takeda; H5N1 reverse genetic reassorted (RG) Indonesia strain (clade 2) vaccine - Shire/US Department of Health and Human Services; H5N1 Vietnam strain (clade 1) vaccine - Takeda/NIAID; Pandemic influenza clade 2 strain vaccine candidate - Takeda; Pandemic influenza vaccine H5N1 - Takeda; Vepacel; Whole virion, vero cell-derived influenza vaccine containing H5N1 HA antigen - Baxter Healthcare Corporation

Latest Information Update: 18 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Baxter International; National Institute of Allergy and Infectious Diseases
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (IM, Injection)
  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top